Azedra
Payments companies reported to CMS as associated with Azedra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Azedra, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Azedra
These are the largest totals companies reported as associated with Azedra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Erik Mittra | Portland, OR | Nuclear Medicine | $6,300.00 |
| Camilo Jimenez | Houston, TX | Endocrinology, Diabetes & Metabolism | $3,515.36 |
| Neeta Pandit-Taskar | Pittsburgh, PA | Nuclear Medicine | $2,666.90 |
| Oksana Hamidi | Dallas, TX | Endocrinology, Diabetes & Metabolism | $2,169.00 |
| Chih-Yi Liao | Chicago, IL | Hematology & Oncology | $2,104.13 |
| Joseph Dillon | Iowa City, IA | Endocrinology, Diabetes & Metabolism | $1,842.00 |
| Lauren Fishbein | Aurora, CO | Endocrinology, Diabetes & Metabolism | $1,150.00 |
| April Teitelbaum | San Diego, CA | Medical Oncology | $337.50 |
| Jorge Diez | East Hartford, CT | Endocrinology, Diabetes & Metabolism | $18.19 |
| Christina Campolo | Cheektowaga, NY | Physician Assistant | $14.19 |
Prescribed Azedra?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.